Study for the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
Enrolling By Invitation
18-99 years
All
Phase
N/A
10 participants needed
1 Location
Brief description of study
The purpose of this study is to continue to collect long term information on the safety of pembrolizumab or pembrolizumab-based combinations that you received or are receiving as part of the protocol you are currently enrolled in, to see how well the drug/s work and how your body reacts to the drug/s long term.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Solid Tumors
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female, Age 18 or older, Advanced unresectable or metastatic tumor(s) Currently enrolled in a sponsored pembrolizumab study and is receiving study treatment or in a Follow-up Phase at the time MK-3475-587 is open
Updated on
01 Aug 2024.
Study ID: 831192
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
